Drug delivery systems for the treatment of diabetes mellitus: State of the art

Current Pharmaceutical Design

Volumn 19, Issue 41, 2013, Pages 7244-7263

  Adams, Gary G ^a   Harding, Stephen E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Analogues; Drug delivery; Injectable; Insulin structure; Synthetic

Indexed keywords

INSULIN; INSULIN DERIVATIVE; LIPOSOME; LONG ACTING INSULIN; POLYMER; PREMIXED INSULIN; RECOMBINANT HUMAN GLUTAMIC ACID DECARBOXYLASE 65; SHORT ACTING INSULIN; UNCLASSIFIED DRUG; VERY LONG ACTING INSULIN; VIAJECT; ANTIDIABETIC AGENT;

AEROSOL; ARTIFICIAL CELL; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG STRUCTURE; DRY POWDER INHALER; GLYCEMIC CONTROL; HUMAN; HYDROGEL; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENCE; INSULIN RELEASE; INSULIN TREATMENT; INTRAPULMONARY DRUG ADMINISTRATION; MICROCAPSULE; ORAL SPRAY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; TRANSDERMAL DRUG ADMINISTRATION; ANIMAL; BLOOD; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANIMALS; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; TREATMENT OUTCOME;

EID: 84890892836     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990367     Document Type: Review

References (162)

1. Adams GG, Hunter J, Langley J. Is nurse-managed blood glucose control in critical care as safe and effective intensive & critical care nursing. Intensive Crit Care Nurs 2009; 25: 294-305.
2. Adams GG, Cui YX, Mitchell JH, Taylor MJ. Rheological and diffusion properties of a dextra-con A polymer in the presence of insulin and magnesium. Rheol Acta 2006; 45: 611-20.
3. Cameron NE, Eaton SEM, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44(11): 1973-88.
4. Cotter MA, Ekberg K, Wahren J, Cameron E. Effects of Proinsulin C-peptide in Experimental Diabetic Neuropathy: Vascular Actions and Modulation by Nitric Oxide Synthase Inhibition. Diabetes 2003; 52: 1812-7.
5. Adams GGWN, Cui Y. Future alternative therapies in a quest to halt aberrations in diabetes mellitus Biomedicine & Pharmacotherapy. Biomed Pharmacother 2005; 59(6): 296-301.
6. Yadav N, Morris G, Harding S.E, Ang S, Adams GG. Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus Endocr Metab Immune Disord Drug Targets 2009; 9(1): 1-13.
7. (DCCT) D.C.C.T.R, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
8. Simoni RD, Hill RL, Vaughan M. The Discovery of Insulin: the Work of Frederick Banting and Charles Best. J Biol Chem 2002; 277.
9. Cefalu WT, Evolving Strategies for Insulin Delivery and Therapy. Drugs 2004; 64(11): 1149-61.
10. Phillips NB, Wan ZL, Whittaker L, et al. Supramolecular protein engineering: design of zinc-stapled insulin hexamers as a long acting depot. J Biol Chem 2010 285(16): 11755-9.
11. Thevis M, Thomas A, Schänzer W, Insulin. Handb Exp Pharmacol 2010 195: p 209-26.
12. Pouwer F, Hermanns N. Insulin therapy and quality of life. A review. Diabetes Metab Res Rev 2009 2009: Suppl 1:S4-S10.
13. Potti LG, Haines S.T. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps. J Am Pharm Assoc 2009; 49(1): e1-13.
14. Polydefkis M, Griffin JW, McArthur J. New insights into diabetic polyneuropathy JAMA 2003; 290 (10): 1371-6.
15. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 2004; 18(10): 963-83.
16. (UKPDS) U.P.D.S.G, Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998. 352: 837-53.
17. Blundell TL, Dodson GG, Hodgkin DC, Mercola DA. Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 1972; 26: 279-402.
18. De Meyts P. Insulin and its receptor:structure, function and evolution. BioEssays 2004; 26: 1351-62.
19. Adams GGCJ, Sahota T, Tanna S, Taylor MJ. Diabetes mellitus and closed-loop insulin delivery. Biotechnol Genet Eng Rev 2000; 17: 455-96.
20. Adams GG, Liddle A, Langley J. Tight Glycaemic Control in Intensive Care. Protocols in Intensive Therapy Units, ed. S.R. VILLAR 2011: Marban.
21. Joshua IG, Zhang Q, Falcone JC, Bratcher AP, Rodriguez WE, Tyagi SC. Mechanisms of endothelial dysfunction with development of type 1 diabetes mellitus: role of insulin and C-peptide. J Cell Biochem 2005; 96(6): 1149-56.
22. Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ. An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. Diabet Med 2009; 26(8): 803-14.
23. Cucinotta D, Russo GT. Biphasic insulin aspart in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2009; 10(17): 2905-11.
24. Hirsch I.B, Insulin Analogues. New Eng J Med 2005; 352: 174-83.
25. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994. 43: 396-402.
26. Mudaliar S, Lindberg FA, Joyce M, et al. Insulin aspart (B28 Asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999. 22: 1501-6.
27. Garnock-Jones KP, Plosker GL. Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs 2009; 69(8): 1035-57.
28. Garg S.K, Ellis S.L, Ulrich H, Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Exp Opin Pharmacother 2005; 6(4): 643-51
29. Garg S.K, Rosenstock J, Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract 2005; 11(1): 11-7.
30. Dreyer M, Prager R, Robinson A, et al. Efficacy and Safety of Insulin Glulisine in Patients with Type 1 Diabetes. Horm Metab Res 2005 37(11): 702-7.
31. Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes Technol Ther 2010; 12(1): 11-24.
32. Garg S, Ampudia-Blasco F.J, Pfohl M, The use of Rapid-Acting insulin Analogs in Basal-Bolus Regimens in type 1 Diabetes. Endocr Pract 2010; 11: 1-48.
33. Wagner A, Diez J, Schulze-Briese C, Schluckebier G. Crystal structure of ultralente--a microcrystalline insulin suspension. Proteins 2009; 74(4): 1018-27.
34. Forst T, Larbig M, Hohberg C, et al. Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes. Diabetes Obes Metab 2010; 12(5): 437-41.
35. Kannan V, Narayanaswamy P, Gadamsetty D, Hazra P, Khedkar A, Iyer H. A tandem mass spectrometric approach to the identification of O-glycosylated glargine glycoforms in active pharmaceutical ingredient expressed in Pichia pastoris. Rapid Commun Mass Spectrom 2009; 23(7): 1035-42.
36. Tuboi M, Tsuchiya T, Taguchi R, et al. Insulin allergy whose local/systemic reactions were reduced by desensitization with long-acting insulin analog, glargine. Nippon Naika Gakkai Zasshi 2010; 99(1): 133-5.
37. Luzio SD, Beck P, Owens DR. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes. Horm Metab Res 2003; 35(7): 434-8.
38. Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23: 1137-42.
39. Rosenstock J, Schwartz SL, Clark JM, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28 week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-6.
40. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabet Med 2006; 23: 879-86.
41. Kudva YC, Basu A, Jenkins G D, et al. Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes Diabetes Care 2005; 28(1): 10-4
42. Müssig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, Häring HU. Diabetes, insulin, insulin analogues, and cancer. Dtsch Med Wochenschr 2010; 135(18): 924-9.
43. Hermanns N, Kulzer B. Insulin glargine and incidence of cancer--an ongoing debate. J Diabetes Sci Technol 2010; 4(2): 497-8.
44. Barrio Castellanos R. Long-acting insulin analogues (insulin glargine or determir) and continuous subcutaneous insulin infusion in the treatment of type 1 diabetes mellitus in the paediatric population. J Pediatr Endocrinol Metab 2005; 18 (Suppl 1): 1173-9.
45. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21: 1498-504.
46. Sasson K, Marcus Y, Lev-Goldman V, Rubinraut S, Fridkin M, Shechter Y. Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions. J Control Release 2010; 142(2): 214-20.
47. Morales J. Defining the role of insulin detemir in Basal insulin therapy. Drugs 2007; 67(17): 2557-84.
48. Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T. Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract 2008; 81(3): 269-77.
49. Hermansen K, Davies M, Derezinski T, et al. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes Diabetes Care 2006; 29 (6): 1269-74
50. Heise T, Nosek L, Rønn BB, et al. Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes Diabetes 2004; 53(6): 1614-20.
51. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000; 23: 813-9.
52. Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L. No evidence for accumulation of insulin glargine (Lantus): a multiple injection study in patients with Type 1 diabetes. Diabet Med 2002 19: 490-5.
53. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlack M, Heise T. Timeaction profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH and placebo. Diabetes Care 2000; 23: 644-9.
54. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-8.
55. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003; 26: 1490-6.
56. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-71.
57. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-6.
58. Hartman I, Insulin Analogs: Impact on Treatment Success, Satisfaction, Quality of Life, and Adherence. Clin Med Res 2008; 6(2): 54-67.
59. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006; 66: 31-49.
60. Rave K, Bott S, Heinemann L, et al. Time-Action Profile of Inhaled Insulin in Comparison With Subcutaneously Injected Insulin Lispro and Regular Human Insulin. Diabetes Care 2005; 28(5): 1077-82.
61. Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008 149(8): 549-59.
62. Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med 2008; 121(6 Suppl): S9-S19.
63. Roach P. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations Clin Pharmacokinet 2008; 47(9): 595-610.
64. Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical science. Diabetes Obes Metab 2009; 11(1): 5-19.
65. Steiner S, Hompesch M, Pohl R, et al. A novel insulin formulation with a more rapid onset of action. Diabetologia 2008; 51: 1602-6.
66. Steiner S, Hompesch M, Pohl R, et al. Pharmacokinetics and pharmacodynamics of insulin VIAjectTM and regular human insulin when injected subcutaneously directly before a meal in patients with type 1 diabetes. Diabetes 2007; 56(Suppl.1): A9.
67. Biodel:, An open label, multi-center, randomized, parallel group study comparing the efficacy and safety of insulin VIAjectTM and regular human insulin in patients with type 1 diabetes mellitus 2008.
68. Biodel: An open label, multi-center, randomized, parallel group study comparing the efficacy and safety of insulin VIAjectTM and regular human insulin in patients with type 2 diabetes mellitus 2008.
69. Pillemer SR, Carlin D. Protégé Trial Group: Protégé Trial: Teplizumab, a monoclonal antibody, for treatment of type1 diabetes mellitus. Diabetes 2008; 57(Suppl. 1): A585-6.
70. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-8.
71. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3y1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1763-9.
72. Burton AR, Baquet Z, Eisenbarth GS, et al. Central Nervous System Destruction Mediated by Glutamic Acid Decarboxylase-Specific CD4+ T Cells. J Immunol 2010; 184: 4863-70.
73. Fenaltia G, Buckle AM, Structural biology of the GAD autoantigen. Autoimmunity Rev 2010; 9(3): 148-52
74. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Effects of recombinant human glutamic acid decarboxylase (rhGAD65) formulated in alum (GAD-alum) on the progression of type 1 diabetes in new onset subjects 2008.
75. Agardh CD, Cilio CM, Lethagen AL, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19: 238-46.
76. Agardh CD, Lethagen A, Cilio CM, et al. Beta cell function and metabolic control during two years of follow-up after GAD65 dose-escalation immunomodulation in adult-onset autoimmune diabetes. Diabetes 2006; 56(Suppl.1): 1173.
77. MacroGenics JDRF, (JDRF): The Protégé Study: clinical trial of MGA031 in children and adults with recent-onset type 1 diabetes mellitus 2008.
78. Diamyd Therapeutics, AB: A phase III study to investigate the impact of Diamyd in patients newly diagnosed with type 1 diabetes (USA) 2008.
79. Modi P, Mihic M, Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ system. Diabetes Metab Res Rev 2002; 18 (Suppl. 1): S38-42.
80. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J, Bernstein G. 6-month safety and efficacy of lunch-time oral insulin in juvenile type-1 DM subjects receiving basal glargine insulin and pre-breakfast and pre-dinner S.C. regular insulin. Diabetes 2007; 56(Suppl. 1): 2760.
81. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J, Bernstein G, Rosenbloom AL. Comparison of oral insulin spray and subcutaneous regular insulin at mealtime in type 1 diabetes. Diabetes Technol Ther 2007; 9: 372-6.
82. Guevara-Aguirre JG.-AM, Saavedra J. Comparison of pre-prandial s.c. regular insulin vs prandial oral insulin in adult type-1 DM subjects receiving basal s.c. twice daily isophan insulin (NPH). Diabetes 2007; 56 (Suppl. 1): 0474-P.
83. Guevara-Aguirre J, Guevara-Aguiree M, Saavedra J, Rosenbloom A, Bernstein G. Insulin analogue (basal + pre-prandial injection) vs. human insulin (basal injection + prandial oral insulin (Generex Oral-lynTM) in type-1 diabetes mellitus: a 372-day comparison Diabetes 2008; 57(Suppl.1): A559-A560.
84. Generex Biotechnology Corporation, Active comparator study of Generex Oral-LynTM spray and injected human insulin online 2008.
85. Rosenstock J, Bergenstal R, Defronzo RA, et al. 0008 Study Group: Efficacy and safety of technosphere inhaled insulin compared with technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008; 31: 2177-82.
86. Boss AH, Baughman RA, Evans SH, Firsov I, Kramer DA, Richardson P. A 3 month comparison in type 1 diabetes of inhaled Technosphere®/insulin (TI) to sc administered rapid-acting insulin analogue (RAA) as prandial insulin in a basal/prandial regimen Diabetes 2006; 55 (Suppl.1): A97.
87. Rave K, Pfutzner A, Heise T, Boss AH. Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care 2007; 30: 2307-8.
88. Tu N, Kramer D, Baughman R. Inhaled Technosphere®/insulin improves glycemic control without weight gain [abstract]. Diabetes 2007; 56 (Suppl. 1): A125.
89. Mannkind Corporation, Efficacy and safety of prandial inhalation of Technosphere/insulin in combination with metformin or Technosphere/insulin alone versus 2 oral anti-diabetic agents in subjects with type 2 diabetes 2008.
90. Mannkind Corporation, Safety and efficacy of Technosphere® insulin inhalation powder and Lantus® compared to Humalog® and Lantus® over 16-weeks 2008;
91. Corporation: M, Efficacy and safety in subjects with type 2 diabetes receiving subcutaneous basal insulin and prandial inhalation of Technosphere/insulin versus subcutaneous premixed insulin therapy over a 52-week treatment period and a 4-week follow-up 2008.
92. Mannkind Corporation, Efficacy & safety of inhaled insulin in type 1 diabetes 2008.
93. Mannkind Corporation, Safety of inhaled insulin with type 1 and type 2 diabetes 2008.
94. Lee YCS P, Yalkowsky SH. Systemic delivery of insulin via an enhancer-free ocular device. J Pharm Sci 1997; 86(12): 1361-4.
95. Chiou GCY. Systemic ocular route delivery of insulin presents faster absorption and escape of hepatic first pass metabolism Annu Rev Pharmacol 1991; 31(1): 457-67.
96. Jabbal-Gill IF, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 1998; 16(20): 2039-46.
97. Cernea SARI. Noninjectable methods of insulin administration. Drugs Today 2006; 42 (6): 405-24.
98. Gizurarson SABE. Intranasal administration of insulin to humans. Diabetes Res Clin Pract 1991; 12(2): 71-84.
99. Turker SOE, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004; 26 (3): 137-42.
100. Drejer KV, Bech K, Hansen P, Sorensen AR, Mygind N. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. Diabetic Med 1992; 9(4): 335-40.
101. Jacobs MAS, RH, Jap-A-Joe K, Nauta JJ, Andersen PM, Heine RJ. The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers. Diabetes 1993; 42(11): 1649-55.
102. Moses ACG, Carey MC, Flier JS. Nasal absorption of insulin: enhancement by hydrophobic bile salts Diabetes 1983; 32(11): 1040-7.
103. Nolte MSTC, Salamon E, Moses A, Longenecker J, Flier J, Karam JH. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Hormone Metabolic Res 1990; 22(3): 170-4.
104. Bruce DGC, Storlien LH, Borkman M, Kraegen EW. Mealtime intranasal insulin delivery in Type 2 diabetes. Diabetic Med 1991; 8(4): 366-70.
105. Liu LF, Hicks KB, Pectin in controlled drug delivery - a review. Cellulose 2007; 14(1): 15-24.
106. Liu LF, ML Kost J, Hicks KB. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials 2003; 24(19): 3333-43.
107. Cernea SK, Wohlgelernter J, Modi P, Raz I. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycaemic clamp technique. Clin Therapeut 2004; 26(12): 2084-91.
108. Modi P, Mihic M, Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ system. Diabetes Metab Res Rev 2002; 18(Suppl. 1S42): S38-42.
109. Lin YHC CH, Liang HF, et al. Novel nanoparticles for oral insulin delivery via the paracellular pathway Nanotechnology 2007; 18(10): (10): 1-11.
110. Carino G.P.J, and Mathiowitz E., Nanosphere based oral insulin delivery. J Controlled Release 2000; 65(12): 261-9.
111. Mesiha MP, Vejosoth S. Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: Ex vivo and in vivo studies. Int J Pharm 1994; 111(3): 213-6.
112. Yamamoto AT, Rikyuu K, Tsuji T, Fujita T, Murakami M, Muranishi S. Effects of Various Protease Inhibitors on the Intestinal Absorption and Degradation of Insulin in Rats. Pharm Res 1994; 11(10): 1496-500.
113. Morishita IM, Takayama K, Machida Y, Nagai, T. Enteral insulin delivery by microspheres in 3 different formulations using Eudragit® L100 and S100. Int J Pharm 1993; 91(1): 29-37.
114. Sarmento BR, Veiga F, Ferreira D, Neufeld R. Oral Bioavailability of Insulin Contained in Polysaccharide Nanoparticles Biomacromolecules 2007; 8(10): 3054-60.
115. Jain DP, Majumdar DK. Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS Pharm Sci Technol 2005; 6(1): E100-7.
116. Wua ZM, Zhoub L, Guoa X D, et al. HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int J Pharm 2012; 425: 1-8.
117. Yeh THH, Tseng MT, Lee PL, Sonjae K, Ho YC, Sung HW. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 2011; 32(26): 6164-73.
118. Sonaje K, Lin YH, Juang JH, et al. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009; 30(12): 2329-39.
119. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Rel 2001; 70: 1-20.
120. Damge C, Pinto Reis C, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv 2008; 5: 1-24.
121. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006; 2: 8-21.
122. Damgé C, Michel C, Aprahamian M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier 1988; 37: 246-51.
123. Aprahamian M, Michel C, Humbert W, Devissaguet JP, Damgé C. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell 1987. 61: 69-76.
124. Damgé C, Michel C, Aprahamian M, Couvreur P, Devissaguet J. Nanocapsules as carriers for oral peptide delivery. J Control Rel 1990; 13: 233-9.
125. Damgé C, Aprahamian M, Humbert W, Pinget M. Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J Pharm Pharmacol 2000; 52: 1049-56.
126. Damgé C, Vranckx H, Balschmidt P, Couvreur P. Poly(alkylcyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 1997; 86: 1403-9.
127. Damgé C, Hillaire-Buys D, Puech R, Hoeltzel A, Michel C, Ribes G. Effects of orally administered insulin nanocapsules in normal and diabetic dogs. Diab Nutr Metab 1995; 8: 3-9.
128. Sai P, Damgé C, Rivereau A. S, Hoeltzel A, Gouin E. Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces incidence of diabetes in non obese diabetic mice. J Autoimmun 1996; 9: 713-22.
129. Radwan MA, Aboul-Enein HY. The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J Microencapsul 2002; 19: 225-35.
130. Radwan M.A, Enhancement of absorption of insulin-loaded polyisobutylcyanoacrylate nanospheres by sodium cholate after oral and subcutaneous dministration in diabetic rats. Drug Dev Ind Pharm 2001; 27: 981-9.
131. Mesiha MS, Sidhom MB, Fasipe B. Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles. Int J Pharm 2005; 288: 289-93.
132. Cournarie F, Auchere D, Chevenne D, Lacour B, Seiller M, Vauthier C. Absorption and efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic rats. Int J Pharm 2002; 242: 325-8.
133. Aboubakar M, Puisieux F, Couvreur P, Deyme M, Vauthier C. Study of the mechanism of insulin encapsulation in poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. J Biomed Mater Res 1999; 47: 568-76.
134. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2006; 2: 53-65.
135. Choudhari KB, Labhasetwar V, Dorle AK. Liposomes as a carrier for oral administration of insulin: Effect of formulation factors. J Microencapsul 1994; 11: 319-25.
136. Sarmento B, Martins S, Ferreira D, Souto EB. Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomed 2007; 2: 743-9.
137. Zhang N, Ping Q, Huang G, Han X, Cheng Y, Xu W. Transport characteristics of wheat germ agglutinin-modified insulin-liposomes and solid lipid nanoparticles in a perfused rat intestinal model. J Nanosci Nanotechnol 2006; 6: 2959-66.
138. Yang R, Gao R. C, Cai C. F, et al. Preparation of gel-core-solid lipid nanoparticle: A novel way to improve the encapsulation of protein and peptide. Chem Pharm Bull 2010; 58: 1195-202.
139. Serra M, Correia C, Malpique R, et al. Microencapsulation technology: a powerful tool for integrating expansion and cryopreservation of human embryonic stem cells. PLoS ONE 2011; 6(8): e23212.
140. Sargent CY, Kinney MA, Hiatt LA, Carpenedo RL. Hydrodynamic modulation of embryonic stem cell differentiation by rotary orbital suspension culture. Biotechnol Bioeng 2010; 105: 611-26.
141. Li L, Davidovich AE, Schloss JM, et al. Neural lineage differentiation of embryonic stem cells within alginate microbeads. Biomaterials 2011; 32(20): 4489-97.
142. Tendulkar S, Mirmalek-Sani SH, Childers C, Saul J, Opara EC, Ramasubramanian M.K. A three-dimensional microfluidic approach to scaling up microencapsulation of cells. Biomed Microdevices 2012;
143. Kerby ABS, Westberg H, Jones P, King A. Immunoisolation of Islets in High Guluronic Acid Barium-Alginate Microcapsules Does Not Improve Graft Outcome at the Subcutaneous Site. Artif Organs 2012; 2012: 1525-94.
144. Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging transdermal drug delivery system. J. Pharm Pharmacol 2012; 64(1): 11-29.
145. Martanto W, Davis S. P, Holiday N. R, et al. Transdermal Delivery of Insulin Using Microneedles in vivo. Pharmaceutical Res 2004; 21(6): 947-952.
146. Capes S, Hunt D, Malmberg K, et al. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000. 355(15): 773-8.
147. Robinson L, Van Soeren M. Insulin resistance and hyperglycaemia in critical illness. AACN Clin Issues 2004; 15(1): 45-62.
148. Guerci B, Kearney-Schwartz A, Bohme P, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. I. Physiology and methods for exploring the endothelial function. Diabetes Metab 2001; 27 425-34.
149. Verma S, Maitland A, Weisel RD, et al. Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: Reversal with endothelin antagonism. J Thorac Cardiovasc Surg 2002; 123: 1120-4.
150. Vanhorebeek I, Langouche L, Van den Berghe G. Glycemic and nonglycemic effects of insulin: how do they contribute to a better outcome of critical illess? Curr Opin Crit Care 2005; 11: 304-11.
151. Van den Berghe G, Wilmer A, Hermans G. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-61.
152. Brange J. Galenics of Insulin The Physicochemical and Pharmaceutical Aspects of Insulin and Insulin Preparations. Berlin: Springer 31 1987.
153. Bergeron L, Filobelo LF, Galkin O, Vekilov PG. Thermodynamics of the hydrophobicity in crystallization of insulin. Biophys J 2003; 85: 3935-42.
154. Gao F, Gao E, Yue TL, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischaemiareperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002; 105: 1497-502.
155. Lazar H, Chipkin S, Fitzgerald C, Bao Y, Cabral H, Apstein C. Tight glycaemic control in diabetic coronary artery bypass graft patients improves peri-operative outcomes and decreases recurrent ischaemic events. Circulation 2004; 109: 1497-502.
156. Liu G, Docherty JC, Rendell JCT, Clanachan AS, Lopaschuk GD. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischaemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 2002; 39: 718-25.
157. Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically Ill patients. N Engl J Med 2001; 345(19): 1359-67.
158. Burge MR, Castillo KR, Schade DS. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care 1997; 20: 152-5.
159. Nau KC, Lorenzetti RC, Cucuzzella M, Devine T, Kline J. Glycemic control in hospitalized patients not in intensive care: beyond sliding-scale insulin. Am Fam Physician 2010; 81(9): 1130-5.
160. Action to Control Cardiovascular Risk in Diabetes Study (ACCORD) Group, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
161. ADVANCE Collaborative Group P A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
162. Skyler JSBR, Bonow RO, Buse J, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Am College Cardiol 2009; 53(3): 298-304.